P154. Outcome analysis of neoadjuvant chemotherapy in patients diagnosed with triple negative breast cancer in routine clinical practice
Louise MagillJuliette MurrayAlison LanniganJennifer McIlhennyDermot MurphyChristine ObondoJonathan HicksSarah SlaterTareq AbdullahMartina MartinezJames Mansell
0
Citation
0
Reference
10
Related Paper
Keywords:
Triple-negative breast cancer
Neoadjuvant Therapy
Complete response
Triple negative
Clinical Practice
Purpose: Triple negative breast cancer (estrogen receptor-negative, progesterone receptor-negative, and HER2/neu negative) is associated with high risk of recurrence and poor prognosis. We investigated the characteristics and prognosis of triple negative early-stage breast cancer. Methods: We reviewed the records of 821 early-stage breast cancer patients treated at our hospital from 1995 to 2005. We studied the differences between a triple negative group compared with a non-triple negative group. Results: Of 821 early-stage breast cancer patients, 200 (24.4%) were classified as triple negative. Large tumors (>2 cm) in the triple negative group were significantly more than those in the non-triple negative group (P=0.042). Histologic and nuclear grade of the triple negative group were significantly higher than those of the non-triple negative group (P<0.001). The median follow-up time is 50 months (1~135). There have been 50 local recurrences, 98 distant metastases, and 65 deaths. There were high rates of local recurrence in the triple negative group but no difference in 5-year disease free survival rates (P=0.178). The 5-year overall survival rate showed 85% in the triple negative group but 92.8% in the non-triple negative group (P=0.008). The relative risk for overall survival was 1.93 times higher in the triple negative group. Conclusion: Triple negative breast cancer patients in early stages have poor pathologic findings and prognoses. Careful treatment and follow-up are important and further investigation is necessary for triple negative breast cancer. (J Korean Surg Soc 2009;77:37-42)
Triple-negative breast cancer
Triple negative
Cite
Citations (0)
Background:The aim of this study was to compare the clinicopathological characteristics of Triple Negative Breast Carcinomas with Non Triple Negative Breast Carcinomas (NTNBC).Evaluation of expression of Epidermal Growth Factor Receptor (EGFR), CK5/6 in TNBC and their comparison with NTNBC was done.Methods: 25 TNBC and 35 NTNBC were selected.The clinicopathological parameters of these two groups were compared.Each group was further immunostained for basal markers(CK5/6 and EGFR).The expression of markers in these two groups was studied and compared with each other. Results:The mean age of TNBC and NTNBC were 47 and 49 years respectively.The majority (48%) of cases from TNBC as well as NTNBC (45%)were in size range of 2-5 cm(T2 stage).IDC-NOS was predominant histological type seen in 92% of TNBC and 100% NTNBC.TNBCs had a significantly higher tumor grade than NTNBC at presentation.LVI was seen in 40% TNBC cases and 42% NTNBC cases.Majority (52%) of TNBC cases were node negative while majority (37.14%) of NTNBC cases belonged to N1 stage.IIA was the most common stage in 36% TNBC cases .In NTNBC, majority of the cases (34%) belonged to Stage IIIA.Expression of basal markers was significantly associated with triple negative breast cancers. Conclusion:TNBCs had a significantly higher tumor grade than NTNBCs at presentation.Expression of basal markers was significantly associated with TNBCs.Since EGFR was significantly associated with triple negative phenotype, TNBC could potentially benefit from EGFR targeted therapeutic strategies.
Triple-negative breast cancer
Triple negative
Basal (medicine)
Cite
Citations (1)
Objective To analyze the relationship of clinicopathologic Features and prognosis of triple negative breast cancer. Methods A total of 196 cases with operable breast cancer received in our hospital between January 2002 and February 2007 were analyzed. We used immunohistochemistry to determine Her2, ER, and PR status. The patients were divided into the triple negative breast cancer group (ER negative,PR negative, and Her-2 negative)and the non-triple negative breast cancer group. The clinicopathologic features of the two groups were compared. The 3-year disease-free survival (DFS) was analyzed. Results Of the 196 patients, 13.27% (26/196) had triple negative breast cancer. The percentage of cases with tumor exceeded 5 cm or grade Ⅲ was higher in the triple negative group than in the non-triple negative group (P ＜ 0.05 ). No significant difference was found in other clinicopathologic features between the two groups.The 3-year DFS was 84.62% (22/26) in the triple negative group and 92.94% ( 158/170)in the non-triple negative group. Conclusion Compared with non triple negative breast cancer, triple negative breast cancer has an increased possibility of local recurrence or distant metastasis,leading to a poorer prognosis.
Key words:
Triple negative breast cancer; Pathology; Clinical; Prognosis
Triple-negative breast cancer
Triple negative
Cite
Citations (2)
Background: While 18F-Fluoromisonidazole (18F-FMISO) is the most frequently used positron emission tomography (PET) tracer for detecting hypoxia, it has not been studied in a metastatic triple-negative [lack expression of estrogen receptor (ER), progesterone receptor (PR) and human EGF receptor 2 (HER2)] human breast cancer cell xenografts model to our best knowledge. This study focuses on whether 18F-FMISO can detect the hypoxic status of triple-negative human breast cancer (TNBC).Methods: The TNBC cells MDA-MB-231 were successfully inoculated in right forelimb of nude mice. Nude mice models with TNBC xenografts were assessed by micro-PET imaging with 18F-FMISO, and hypoxic status of the TNBC xenografts was determined by immunohistochemistry. We also compared 18F-FDG uptake, the most commonly used PET tracer in clinical practice, with 18F-FMISO uptake to find out its correlation in MDA-MB-231 xenografts.Results: For 18F-FMISO, intestines and liver as well as bladder could be seen in micro-PET images. 18F-FDG showed physiologically high uptake in brain, heart, bladder and intestinal tracts. The quantitative radioactivity of 18F-FMISO and 18F-FDG in tumor were 2.18±0.15 and 3.84±0.54%ID/g, respectively. The quantitative radioactivity of 18F-FMISO and 18F-FDG in muscle were 1.23±0.08 and 0.59±0.09%ID/g, respectively. The tumor-to-muscle ratios were 1.79±0.015 and 7.11±2.84 for 18F-FMISO and 18F-FDG, respectively. Immunofluorescent images from MDA-MB-231 cryosections showed significant hypoxia.Conclusions: 18F-FMISO PET may be used for detection of hypoxia in tumor microenvironment of triple negative human breast cancer.
Triple-negative breast cancer
Triple negative
PET Imaging
Cite
Citations (2)
Triple-negative breast cancer
Complete response
Triple negative
Cite
Citations (0)
Triple-negative breast cancer
Triple negative
Cite
Citations (0)
Breast cancer is a heterogeneous disease that can be classified into diverse subtypes with distinct biology and prognosis. The purpose of this study is to compare clinicopathological features and prognostic of patients with Triple Negative Breast Cancer (TNBC) and non-TNBC. Clinicopathological features and prognosis of 266 patients from north Morocco (56 TNBC and 210 non-TNBC) were evaluated using SPSS 20 software. The incidence of TNBC was 21%. Compared with non-TNBC, TNBC patients tend to be younger at diagnosis and had slightly larger tumors and higher stage. Higher histological grade was strongly associated with TNBC. Lymph nodes and histological type were similar in the two groups. Bone was the most frequently metastatic site in all breast cancers, but TNBC was strongly associated with liver metastases. No significant difference was observed in 5-year Disease-Free Survival (DFS) and 5-year Overall Survival (OS) between TNBC and non-TNBC. In conclusion, TNBC is associated with particular clinicopathological features and poor prognosis compared to non-TNBC.
Triple-negative breast cancer
Triple negative
Cite
Citations (0)
e12592 Background: During last decade, therapeutic arsenal has expanded for metastatic breast cancer (mBC), but few data are available about mTNBC, a poor prognosis subtype. In 2014, UNICANCER (composed of 18 French Comprehensive Cancer Centers) launched the Epidemiological Strategy and Medical Economics (ESME) program to centralize real-world data. This base represents a great opportunity to update the outcomes and the treatment practice patterns of this population. Methods: The ESME-mBC database was built from information systems, treatment databases and patients’ electronic files including quality control processes. All pts who initiated treatment for mBC between 01-Jan-2008 and 31-Dec-2014 were selected. The primary objective of this study was to assess overall survival (OS) of mTNBC pts. TNBC status was defined as ER and PR < 10% in both primary and metastatic disease, as well as the absence of overexpression or amplification of HER2. The secondary objectives were to describe the characteristics of this population, clinical management (duration and sequence of treatments) and to evaluate the prognostic value of several clinical factors (age, distant disease free interval, location and number of metastatic sites) Results: Among 16703 pts in the ESME-mBC database, 2368 (14%) had mTNBC. Median OS over this time period was 14.8 months (95% CI 14-15.6). Median age at diagnosis of mBC was 57 years. For the pts who relapsed, median metastasis free interval was 24 months, while 25.5% of the pts were de novo metastatic. 61% of the pts presented visceral metastasis and 12% had cerebral metastasis as first metastatic site. The pattern of metastatic involvement (visceral and cerebral) and a short metastasis free interval ( < 24 months) were the most important prognostic factors in multivariate analysis. The description of treatment sequences (duration, prognostic value) will be presented. Conclusions: In this real-life setting database, mTNBC remain of poor prognosis despite a trend for a better OS than the historical data available (12-13 ms). This TNBC ESME cohort is one of the largest available and offers an updated assessment of the outcomes of this population.
Triple-negative breast cancer
Cite
Citations (1)
Triple-negative breast cancer
Triple negative
Triple junction
Cite
Citations (1)
Triple-negative breast cancer
Triple negative
Triple test
Cite
Citations (0)